OpenEvidence, AI Search Tool Used by Doctors, Hits $15 Billion Valuation After $250M Raise

4.0 · 10d ago · US · AI

The Facts

  • OpenEvidence raised $250 million in its latest funding round in September at a $15 billion valuation. Ars Technica only
  • The company has attracted nearly $1 billion in investment over the past 18 months from backers including Andreessen Horowitz, Blackstone, Thrive Capital and Sequoia. Ars Technica only
  • OpenEvidence, founded in 2022 by Daniel Nadler and based in Miami, says many of America's 1 million physicians processed more than 42 million prompts last month; the article says nearly two-thirds of US doctors use the tool. Ars Technica only
  • A person close to the company said OpenEvidence booked $100 million in ad buys (current and future advertising commitments) for 2026 as of the end of 2025, and is on track to generate $400 million to $500 million through ads by the end of 2026. Ars Technica only
  • The tool is embedded in electronic health records at hospitals and clinics including Mount Sinai Health System and Memorial Sloan Kettering; NYU Langone also pursued a formal integration after clinicians were already using it. Ars Technica only
Dive deeper · 5 more factsShow less
  • OpenEvidence withdrew from the EU and UK earlier this year over the EU's AI Act. Ars Technica only
  • Nadler said the company will launch clinical trials in the coming weeks with researchers targeting cancer and rare diseases, and plans to apply AI to drug discovery. Ars Technica only
  • Anthropic recently partnered with OpenEvidence to bring healthcare tools to 100 low- and middle-income countries; Alexander Tarashansky, creator of Anthropic's Claude Science, has joined OpenEvidence. Ars Technica only
  • Wolters Kluwer released an AI version of its UpToDate tool in October 2025, nearly two years after OpenEvidence entered the market. Ars Technica only
  • OpenAI offers a competing product, ChatGPT for healthcare, and Anthropic has also released healthcare tools. Ars Technica only

Context

OpenEvidence, a Miami-based AI search and chatbot platform for clinicians, has grown largely by word of mouth and is funded by advertising. It draws on peer-reviewed sources such as the New England Journal of Medicine and JAMA.

Researchers have raised concerns about the accuracy of its results as doctors rely on it more, and critics question whether the ad-based model justifies the valuation. Physicians interviewed said it eased their workloads. The article is based on reporting originally from the Financial Times.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 1.

4 News Editor The story reports a concrete funding event ($250M raise at $15B valuation) for a tech company with notable adoption among US physicians, but it is a business/valuation story of limited broad public impact, with only one independent source.
4 Policy Expert This is a funding and valuation report for a private company, a concrete financial event with some sector relevance, but it has limited direct impact on the public and no governmental action, and it is mostly a business-news story about a single firm's raise and metrics.
4 Global Affairs Analyst This is a funding round and valuation report for a private AI company, a concrete financial event with limited direct public-impact significance beyond the healthcare-tech sector, though its widespread physician use and planned clinical trials add some relevance.
4 Science & Tech Analyst This is a funding round and valuation story for a private AI company, with notable adoption among physicians but no peer-reviewed breakthrough or immediate broad public impact beyond business news, though the planned clinical trials give it some added weight.
4 Business Analyst This reports a private funding round at a $15 billion valuation for a niche clinician AI tool, a notable but company-specific event with limited direct market-wide impact, though it signals strong adoption and ad-revenue growth in healthcare AI.
4 Critical Reader A private funding round at a $15B valuation with a single source is a financial event of limited broad impact, though its use by about two-thirds of US doctors gives it some reach.
3 Informed Citizen This is a funding and valuation story about a private startup, a concrete financial event with limited direct impact on ordinary people, though it touches on physician tools and healthcare AI.

Source

← All stories